Cytori Therapeutics (NASDAQ: CYTX) reported Q2 EPS of ($0.43), $0.04 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.13 million versus the consensus estimate of $2.5 million.

“In the first half of the year, our team has advanced our development pipeline in the U.S. in multiple indications, most notably completing enrollment in our Phase 3 trial in scleroderma. Additionally, investigator-initiated studies are progressing in Europe and Japan, and we have continued to lay a sound foundation for early clinical adoption and profitable revenue growth in Japan and Europe, which can provide near-term revenue and importantly build longer-term strategic value,” said Dr. Marc H. Hedrick, President and Chief Executive Officer for Cytori. “Corporate milestones over the next twelve months include the first readout from our US phase III scleroderma trial in mid-2017, the initiation of an externally funded clinical trial in burn patients later this year, treatment of the first scleroderma patients as part of our compassionate use program, and Japanese revenue growth.”

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.